1 Drugs for HIV Market Overview

• 1.1 Product Overview and Scope of Drugs for HIV
• 1.2 Drugs for HIV Segment by Type
  • 1.2.1 Global Drugs for HIV Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 1.2.3 Integrase Inhibitors
  • 1.2.4 Combination HIV Medicines
  • 1.2.5 Others
• 1.3 Drugs for HIV Segment by Application
  • 1.3.1 Drugs for HIV Sales Comparison by Application: (2021-2027)
  • 1.3.2 Hospital Pharmacies
  • 1.3.3 Retail Pharmacies
  • 1.3.4 Online Pharmacies
  • 1.3.5 Others
• 1.4 Global Drugs for HIV Market Size Estimates and Forecasts
  • 1.4.1 Global Drugs for HIV Revenue 2016-2027
  • 1.4.2 Global Drugs for HIV Sales 2016-2027
  • 1.4.3 Drugs for HIV Market Size by Region: 2016 Versus 2021 Versus 2027

2 Drugs for HIV Market Competition by Manufacturers

• 2.1 Global Drugs for HIV Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Drugs for HIV Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Drugs for HIV Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Drugs for HIV Manufacturing Sites, Area Served, Product Type
• 2.5 Drugs for HIV Market Competitive Situation and Trends
  • 2.5.1 Drugs for HIV Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Drugs for HIV Players Market Share by Revenue
  • 2.5.3 Global Drugs for HIV Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Drugs for HIV Retrospective Market Scenario by Region

• 3.1 Global Drugs for HIV Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global Drugs for HIV Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America Drugs for HIV Market Facts & Figures by Country
  • 3.3.1 North America Drugs for HIV Sales by Country
  • 3.3.2 North America Drugs for HIV Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Drugs for HIV Market Facts & Figures by Country
  • 3.4.1 Europe Drugs for HIV Sales by Country
  • 3.4.2 Europe Drugs for HIV Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Drugs for HIV Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Drugs for HIV Sales by Region
  • 3.5.2 Asia Pacific Drugs for HIV Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Drugs for HIV Market Facts & Figures by Country
  • 3.6.1 Latin America Drugs for HIV Sales by Country
  • 3.6.2 Latin America Drugs for HIV Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Drugs for HIV Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Drugs for HIV Sales by Country
  • 3.7.2 Middle East and Africa Drugs for HIV Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE

4 Global Drugs for HIV Historic Market Analysis by Type

• 4.1 Global Drugs for HIV Sales Market Share by Type (2016-2021)
• 4.2 Global Drugs for HIV Revenue Market Share by Type (2016-2021)
• 4.3 Global Drugs for HIV Price by Type (2016-2021)

5 Global Drugs for HIV Historic Market Analysis by Application

• 5.1 Global Drugs for HIV Sales Market Share by Application (2016-2021)
• 5.2 Global Drugs for HIV Revenue Market Share by Application (2016-2021)
• 5.3 Global Drugs for HIV Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 ViiV Healthcare
  • 6.1.1 ViiV Healthcare Corporation Information
  • 6.1.2 ViiV Healthcare Description and Business Overview
  • 6.1.3 ViiV Healthcare Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 ViiV Healthcare Product Portfolio
  • 6.1.5 ViiV Healthcare Recent Developments/Updates
• 6.2 Gilead Sciences, Inc
  • 6.2.1 Gilead Sciences, Inc Corporation Information
  • 6.2.2 Gilead Sciences, Inc Description and Business Overview
  • 6.2.3 Gilead Sciences, Inc Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 Gilead Sciences, Inc Product Portfolio
  • 6.2.5 Gilead Sciences, Inc Recent Developments/Updates
• 6.3 Merck Sharp & Dohme Corp
  • 6.3.1 Merck Sharp & Dohme Corp Corporation Information
  • 6.3.2 Merck Sharp & Dohme Corp Description and Business Overview
  • 6.3.3 Merck Sharp & Dohme Corp Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 Merck Sharp & Dohme Corp Product Portfolio
  • 6.3.5 Merck Sharp & Dohme Corp Recent Developments/Updates
• 6.4 Bristol-Myers Squibb Company
  • 6.4.1 Bristol-Myers Squibb Company Corporation Information
  • 6.4.2 Bristol-Myers Squibb Company Description and Business Overview
  • 6.4.3 Bristol-Myers Squibb Company Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Bristol-Myers Squibb Company Product Portfolio
  • 6.4.5 Bristol-Myers Squibb Company Recent Developments/Updates
• 6.5 Janssen Pharmaceuticals, Inc.
  • 6.5.1 Janssen Pharmaceuticals, Inc. Corporation Information
  • 6.5.2 Janssen Pharmaceuticals, Inc. Description and Business Overview
  • 6.5.3 Janssen Pharmaceuticals, Inc. Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Janssen Pharmaceuticals, Inc. Product Portfolio
  • 6.5.5 Janssen Pharmaceuticals, Inc. Recent Developments/Updates
• 6.6 Theratechnologies Inc.
  • 6.6.1 Theratechnologies Inc. Corporation Information
  • 6.6.2 Theratechnologies Inc. Description and Business Overview
  • 6.6.3 Theratechnologies Inc. Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 Theratechnologies Inc. Product Portfolio
  • 6.6.5 Theratechnologies Inc. Recent Developments/Updates
• 6.7 Mylan Pharmaceuticals Inc.
  • 6.6.1 Mylan Pharmaceuticals Inc. Corporation Information
  • 6.6.2 Mylan Pharmaceuticals Inc. Description and Business Overview
  • 6.6.3 Mylan Pharmaceuticals Inc. Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Mylan Pharmaceuticals Inc. Product Portfolio
  • 6.7.5 Mylan Pharmaceuticals Inc. Recent Developments/Updates
• 6.8 Genentech, Inc.
  • 6.8.1 Genentech, Inc. Corporation Information
  • 6.8.2 Genentech, Inc. Description and Business Overview
  • 6.8.3 Genentech, Inc. Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Genentech, Inc. Product Portfolio
  • 6.8.5 Genentech, Inc. Recent Developments/Updates
• 6.9 AbbVie Inc.
  • 6.9.1 AbbVie Inc. Corporation Information
  • 6.9.2 AbbVie Inc. Description and Business Overview
  • 6.9.3 AbbVie Inc. Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 AbbVie Inc. Product Portfolio
  • 6.9.5 AbbVie Inc. Recent Developments/Updates

7 Drugs for HIV Manufacturing Cost Analysis

• 7.1 Drugs for HIV Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Drugs for HIV
• 7.4 Drugs for HIV Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Drugs for HIV Distributors List
• 8.3 Drugs for HIV Customers

9 Drugs for HIV Market Dynamics

• 9.1 Drugs for HIV Industry Trends
• 9.2 Drugs for HIV Growth Drivers
• 9.3 Drugs for HIV Market Challenges
• 9.4 Drugs for HIV Market Restraints

10 Global Market Forecast

• 10.1 Drugs for HIV Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Drugs for HIV by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Drugs for HIV by Type (2022-2027)
• 10.2 Drugs for HIV Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Drugs for HIV by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Drugs for HIV by Application (2022-2027)
• 10.3 Drugs for HIV Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Drugs for HIV by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Drugs for HIV by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Integrase Inhibitors
Combination HIV Medicines
Others

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
ViiV Healthcare
Gilead Sciences, Inc
Merck Sharp & Dohme Corp
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Theratechnologies Inc.
Mylan Pharmaceuticals Inc.
Genentech, Inc.
AbbVie Inc.